With this approval, HUMIRA, an anti-TNF monoclonal antibody, offers pediatric patients from five years of age with moderately to severely active ulcerative colitis the first subcutaneous anti-TNF treatment option 1 Approval based on results from the pivotal Phase 3 ENVISION I study, the largest clinical trial in pediatric ulcerative colitis to date, showing HUMIRA provided significant rates of response and remission … With this approval, HUMIRA, an anti-TNF monoclonal antibody, offers pediatric patients from five years of age with moderately to severely active ulcerative colitis (UC) the first subcutaneous anti-TNF treatment option 1 Approval based on results from the pivotal Phase 3 ENVISION I study, the largest clinical trial in pediatric ulcerative colitis to date, showing HUMIRA provided significant rates of response and remission both at week 8 and 52
SKYRIZI® is now listed for public payer coverage across all Canadian jurisdictions.
ABBVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company, announced today that SKYRIZI® (risankizumab) is now listed as a special authorization drug on the formulary of Prince Edward Island for the treatment of moderate to severe plaque psoriasis. With the addition of the PEI formulary listing, SKYRIZI® is now listed for public payer coverage in all Canadian jurisdictions. SKYRIZI® is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally. “New psoriasis treatments, which improve the quality of patients lives, are always welcome. In clinical trials, SKYRIZI® demonstrated high levels of skin clearance and persistence of effect. It is great news to know that people living in PEI with moderate-to-severe psoriasis, can now access this drug under the provincial formulary,” shares